Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zevalin Price Negotiations Will Be Model For Medicare Part B, Scully Says

Executive Summary

Idec's experience securing Medicare reimbursement for Zevalin should be considered the model for how coverage decisions will work for new products once Part B payment reforms are implemented in 2005, former CMS Administrator Tom Scully said

You may also be interested in...



Who Needs The BBB? Aduhelm Shows Medicare Price ‘Negotiation’ Is Already Here

Biogen is making clear that its decision to cut the price of the Alzheimer’s therapy Aduhelm is in no way tied to the upcoming US Medicare coverage decision for the treatment. But it still shows how Medicare can already ‘negotiate’ prices even without explicit statutory authority.

The Virtues Of Predictability: US Medicare’s Review Of Aduhelm Coverage

Medicare’s decision to initiate a formal review of coverage for the newly approved Alzheimer’s agent is a highly unsettling development in many respects. It is also probably the best possible news for Biogen and Eisai at this point.

Zevalin, Bexxar Off-Label Coverage Decision Affirms Status Quo

Medicare contractors will retain the discretion to determine when to cover Biogen Idec's Zevalin and GlaxoSmithKline's Bexxar for off-label use in non-Hodgkin's lymphoma under a proposed coverage determination issued by the Centers for Medicare & Medicaid Services May 4

Related Content

Latest News
UsernamePublicRestriction

Register

PS043191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel